Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Status: Enrolling
Updated:  9/29/2017
Research Site
mi
from
The Bronx, NY
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Status: Enrolling
Updated: 9/29/2017
Research Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Status: Enrolling
Updated:  9/29/2017
Clinical Research Facility
mi
from
Williamsville, NY
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Status: Enrolling
Updated: 9/29/2017
Clinical Research Facility
mi
from
Williamsville, NY
Click here to add this to my saved trials
Vitamin D to Improve Endothelial Function in SLE
Vitamin D Repletion to Improve Endothelial Function in Lupus Patients
Status: Enrolling
Updated:  9/29/2017
Medical University of South Carolina
mi
from
Charleston, SC
Vitamin D to Improve Endothelial Function in SLE
Vitamin D Repletion to Improve Endothelial Function in Lupus Patients
Status: Enrolling
Updated: 9/29/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Transitional Telehealth Home Care: REACH
Transitional Telehealth Home Care: REACH
Status: Enrolling
Updated:  9/29/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Transitional Telehealth Home Care: REACH
Transitional Telehealth Home Care: REACH
Status: Enrolling
Updated: 9/29/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Transitional Telehealth Home Care: REACH
Transitional Telehealth Home Care: REACH
Status: Enrolling
Updated:  9/29/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Transitional Telehealth Home Care: REACH
Transitional Telehealth Home Care: REACH
Status: Enrolling
Updated: 9/29/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Designing Food Voucher Programs to Reduce Disparities in Healthy Diets
Coupons for Healthy Intake Using Variable Economic Strategies (CHIVES)
Status: Enrolling
Updated:  10/2/2017
University of California
mi
from
San Francisco, CA
Designing Food Voucher Programs to Reduce Disparities in Healthy Diets
Coupons for Healthy Intake Using Variable Economic Strategies (CHIVES)
Status: Enrolling
Updated: 10/2/2017
University of California
mi
from
San Francisco, CA
Click here to add this to my saved trials
Personal Genomics for Preventive Cardiology
A Pilot Randomized Trial of Personal Genomics for Preventive Cardiology
Status: Enrolling
Updated:  10/3/2017
Stanford Medical Center
mi
from
Stanford, CA
Personal Genomics for Preventive Cardiology
A Pilot Randomized Trial of Personal Genomics for Preventive Cardiology
Status: Enrolling
Updated: 10/3/2017
Stanford Medical Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Cerebral Autoregulation and Vasospasm in Patients With TBI
Cerebral Autoregulation and Vasospasm in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  10/3/2017
R Adams Cowley Shock Trauma Center, University of Maryland Medical Center
mi
from
Baltimore, MD
Cerebral Autoregulation and Vasospasm in Patients With TBI
Cerebral Autoregulation and Vasospasm in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 10/3/2017
R Adams Cowley Shock Trauma Center, University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
HDL Increased Plaque Stabilization in the Elderly
Status: Enrolling
Updated:  10/4/2017
Johns Hopkins Unversity School of Medicine
mi
from
Baltimore, MD
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
HDL Increased Plaque Stabilization in the Elderly
Status: Enrolling
Updated: 10/4/2017
Johns Hopkins Unversity School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
Magnetic Resonance Angiography (MRA) in the Diagnosis of Atherosclerotic Disease Using High Field (3T) MRI Scanners: A Pilot Technical Development Study
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
Magnetic Resonance Angiography (MRA) in the Diagnosis of Atherosclerotic Disease Using High Field (3T) MRI Scanners: A Pilot Technical Development Study
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest
Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest
Status: Enrolling
Updated:  10/5/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest
Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest
Status: Enrolling
Updated: 10/5/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Charlotte, NC
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Medford, OR
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Seneca, SC
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Seneca, SC
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Union, SC
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Newport News, VA
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Newport News, VA
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Winnipeg,
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Winnipeg,
Click here to add this to my saved trials
West Philadelphia Consortium Randomized Control Trial
West Philadelphia Consortium to Address Disparities
Status: Enrolling
Updated:  10/10/2017
University of Pennsylvania Center for Community Based Research and Health Disparities
mi
from
Philadelphia, PA
West Philadelphia Consortium Randomized Control Trial
West Philadelphia Consortium to Address Disparities
Status: Enrolling
Updated: 10/10/2017
University of Pennsylvania Center for Community Based Research and Health Disparities
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Canagliflozin on Intravascular Volume and Hemodynamics
A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure
Status: Enrolling
Updated:  10/10/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Effects of Canagliflozin on Intravascular Volume and Hemodynamics
A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure
Status: Enrolling
Updated: 10/10/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men
Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men
Status: Enrolling
Updated:  10/11/2017
Tufts University
mi
from
Boston, MA
Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men
Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men
Status: Enrolling
Updated: 10/11/2017
Tufts University
mi
from
Boston, MA
Click here to add this to my saved trials
BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI
Functional Magnetic Resonance Angiographic Imaging Using Blood Oxygen Level Determination (BOLD) Assessment as a Surrogate of Improved Skeletal Muscle Oxygenation After Endovascular Therapy for the Treatment of Chronic Lower Limb Ischemia
Status: Enrolling
Updated:  10/11/2017
St. Johns Hospital
mi
from
Springfield, IL
BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI
Functional Magnetic Resonance Angiographic Imaging Using Blood Oxygen Level Determination (BOLD) Assessment as a Surrogate of Improved Skeletal Muscle Oxygenation After Endovascular Therapy for the Treatment of Chronic Lower Limb Ischemia
Status: Enrolling
Updated: 10/11/2017
St. Johns Hospital
mi
from
Springfield, IL
Click here to add this to my saved trials
The Northwest Coalition for Primary Care Practice Support
The Northwest Coalition for Primary Care Practice Support
Status: Enrolling
Updated:  10/11/2017
GroupHealthCoop
mi
from
Seattle, WA
The Northwest Coalition for Primary Care Practice Support
The Northwest Coalition for Primary Care Practice Support
Status: Enrolling
Updated: 10/11/2017
GroupHealthCoop
mi
from
Seattle, WA
Click here to add this to my saved trials
Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training
Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training
Status: Enrolling
Updated:  10/14/2017
Children's Hospital Boston
mi
from
Boston, MA
Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training
Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training
Status: Enrolling
Updated: 10/14/2017
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated:  10/17/2017
Alaska Heart Institute
mi
from
Anchorage, AK
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated: 10/17/2017
Alaska Heart Institute
mi
from
Anchorage, AK
Click here to add this to my saved trials
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated:  10/17/2017
Palo Alto Medical Foundation
mi
from
Palo Alto, CA
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated: 10/17/2017
Palo Alto Medical Foundation
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated:  10/17/2017
Minneapolis Heart Institute Foundation
mi
from
Minneapolis, MN
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated: 10/17/2017
Minneapolis Heart Institute Foundation
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated:  10/17/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated: 10/17/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated:  10/17/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated: 10/17/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated:  10/17/2017
West Penn Allegheny Health System
mi
from
Pittsburgh, PA
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated: 10/17/2017
West Penn Allegheny Health System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated:  10/17/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated: 10/17/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated:  10/17/2017
Intermountain Healthcare
mi
from
Salt Lake City, UT
Diagnostic Investigation of Sudden Cardiac Event Risk
Identifying Markers That Predict Ventricular Arrhythmia Risk
Status: Enrolling
Updated: 10/17/2017
Intermountain Healthcare
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Christiana Care
mi
from
Newark, DE
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Christiana Care
mi
from
Newark, DE
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Bradenton Cardiology Center
mi
from
Bradenton, FL
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Bradenton Cardiology Center
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
First Coast Cardiovascular Institute
mi
from
Jacksonville, FL
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
First Coast Cardiovascular Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Cardiovascular Associates
mi
from
Elk Grove Village, IL
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Cardiovascular Associates
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Midwest Cardiovascular Research Foundation
mi
from
Davenport, IA
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Midwest Cardiovascular Research Foundation
mi
from
Davenport, IA
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Kings Daughters Medical Center
mi
from
Ashland, KY
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Kings Daughters Medical Center
mi
from
Ashland, KY
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Columbia University Medical Center
mi
from
New York, NY
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Hillsboro Cardiology
mi
from
Hillsboro, OR
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Hillsboro Cardiology
mi
from
Hillsboro, OR
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Central Bucks Specialists
mi
from
Doylestown, PA
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Central Bucks Specialists
mi
from
Doylestown, PA
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Medical University of South Carolina
mi
from
Charleston, SC
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
South Carolina Heart Center
mi
from
Columbia, SC
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
South Carolina Heart Center
mi
from
Columbia, SC
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
University of Virginia
mi
from
Charlottesville, VA
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated:  10/17/2017
Centra Cardiovascular Group
mi
from
Lynchburg, VA
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Status: Enrolling
Updated: 10/17/2017
Centra Cardiovascular Group
mi
from
Lynchburg, VA
Click here to add this to my saved trials